President Joe Biden‘s reelection campaign recently criticized Sen. Tim Scott (R-S.C.) for promoting drug price caps that he previously voted against. This dispute revolves around senior citizen drug costs and the Inflation Reduction Act.
As per the report by The Hill, the Biden campaign released a video highlighting Scott’s contradictory stance. It showcased Scott praising the capping of senior drug costs while simultaneously arguing for the elimination of the Inflation Reduction Act, which he had opposed.
The video includes a clip from Scott’s recent interview with KCCI Des Moines, where he said, “One of the things we did for our seniors in the last Congress, not this Congress, last Congress, is we were able to cap out-of-pocket expenses, and that's a really good thing.”
Scott was then shown in a Senate hearing, criticizing the legislation that President Biden signed into law in August 2022.
“I would simply eliminate the IRA, the Inflation Reduction Act, which of course is a lie from the pit of hell. I would start the process of gutting that legislation,” he said.
The Inflation Reduction Act, a notable achievement for Biden, permits Medicare to negotiate prescription drug prices and caps insulin costs at $35 for seniors. The Act has been in the crosshairs of lawmakers seeking to roll back some of its provisions, like tax incentives for clean energy and electric vehicles.
Previously, Biden has called out other lawmakers, such as Rep. Marjorie Taylor Greene (R-Ga.), for opposing legislation he endorsed but then promoting its benefits in their districts, like investments in manufacturing.
Read Next: Trump Pressured To Disclose Whether He Plans To Blame His Lawyers In Election Interference Case
Image via Shutterstock
Engineered by Benzinga Neuro, Edited by Pooja Rajkumari
The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.